Carly Helfand

Biography for Carly Helfand

Carly Helfand, News Editor

Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfand@fiercemarkets.com and follow her on Twitter at @CarlyHFierce.

Articles by Carly Helfand

Protein Sciences halts Connecticut expansion in response to governor's use of rival flu shot

Flu vaccine maker Protein Sciences may be abandoning its expansion plans in Connecticut, opting instead to build out its New York-based manufacturing site. But it's not for any of the reasons one might expect.

Advaxis inks pact with Incyte to test cervical cancer vaccine combo

Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.

GSK nabs pipeline prospects, conjugate vaccine tech with GlycoVaxyn buyout

Since forging a scientific collaboration in 2012, GlaxoSmithKline has held a minority stake in Swiss biotech GlycoVaxyn. Now, it's forking over $190 million to acquire the remaining shares and take full ownership of the company.

GSK lays off 27 vaccine researchers in Montana

As GlaxoSmithKline prepares to fold in the bulk of Novartis' vaccines unit--headed its way after their April 2014 multibillion-dollar asset swap--it's changing things up a little. And that includes closing the R&D branch of its vaccines lab in Hamilton, MT, this year.

UPDATED: Valeant grabs Provenge and other Dendreon assets with raised $400M bid

It's official: Valeant will be the new owner of Dendreon's Provenge.

Scientists in search of next-generation Ebola vaccines as outbreak dwindles

The current Ebola outbreak may be starting to wane, but scientists agree they'll need a stockpile of vaccines to tackle the next one. And that means developing next-generation shots that can fight off multiple strains.

Measles-jab maker Merck says it can only do so much to encourage vaccination

As the Disneyland measles outbreak continues to spread, some are pointing the finger at Merck, maker of the only U.S.-approved measles vaccine. But when it comes to encouraging the public to get vaccinated, there's a limit on how much the company can do, its R&D chief says.

Dendreon lands stalking-horse bid for Provenge from serial acquirer Valeant

Bankrupt Dendreon has finally found a taker for its flailing cancer vaccine, Provenge. It seems serial acquirer Valeant is ready to foray into oncology--and thinks it can turn the therapy around.

Takeda drops DTaP/sIPV development to focus on 'higher-impact' programs

After creating a global specialty unit for its vaccines business and tapping a new development head last fall, Takeda now plans to drop a Phase II Diphtheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV) program in Japan to focus on markets where it can make a bigger splash.

Pfizer's Prevenar price cut 'inadequate,' critics say

Last week, international charity Médecins Sans Frontières called on Pfizer to drop its price on pneumococcal vaccine Prevenar 13. The pharma giant responded earlier this week, lopping 20 cents off the per-dose cost through vaccine alliance GAVI. But the way MSF sees it, that's not good enough.